










Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			<i>Complete if Known</i> Application Number: 10/715,912 Filing Date: November 18, 2003 First Named Inventor: Hinz Art Unit: 1616 Examiner Name: Lamm, M. Attorney Docket Number: 3364.31US08	
Sheet	1	of		




U.S. PATENT DOCUMENTS				
EXAMINER INITIAL <sup>1</sup>	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number-Kind Code <sup>2</sup> (if known)		
		US-4,237,118	12-02-1980	Howard
		US-5,019,594	05-28-1991	Wurtman et al.
		US-5,084,007	01-28-1992	Malin et al.
		US-5,977,099	11-02-1999	Nickolson
		US-6,048,728	04-11-2000	Inlow et al.
		US-6,335,323	01-01-2002	Worsley
		US-6,384,088	05-07-2002	Hinz
		US-6,548,551	04-15-2003	Hinz
		US-6,759,437	07-06-2004	Hinz

FOREIGN PATENT DOCUMENTS					
EXAMINER INITIAL <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			


NON PATENT LITERATURE DOCUMENTS			
EXAMINER INITIAL <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		ABELL, "Placebo controlled double-blind trial fluvoxamine maleate in the obese", J. Psychosomatic Res, 30(2): 143-146 (1986).	
		BOUCHARD, "Citalopram and viloxazine in the treatment of depression by means of slow drop infusion, A double blind comparative trial", J Affect Disord, 46(1): 51-8 (1997).	
		MAREK ET AL., "A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action", Psychopharmacology 109:2-11 (1992).	
		MOON, "The Effects of Psychomotor Performance of Fluvoxamine Versus Mianserin in Depressed Patients in General Practice", BJCP, 45(4): 259-262.	

EXAMINER SIGNATURE		DATE CONSIDERED	
--------------------	---	-----------------	---


<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.



<b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)			<b>ATTY DOCKET NO.:</b> H76.2N-8151- US06		<b>APPLICATION NO.:</b> 10/715912	
			<b>APPLICANT:</b> Martin C. Hinz			
			<b>FILING DATE:</b> November 18, 2003		<b>GROUP:</b> 1616	
<b>REFERENCE DESIGNATION</b>			<b>U.S. PATENT AND PUBLISHED APPLICATION DOCUMENTS</b>			
<b>EXAM'S INIT.</b>		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS/ SUBCLASS</b>	<b>FILING DATE IF APPROPRIATE</b>
Ull	AA	4,377,595	03/22/83	Wurtman	434/319	
Ull	AB	5,189,064	02/23/93	Blum et al.	514/561	
Ull	AC	5,939,076	08/17/99	Allocca	424/400	
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
<b>FOREIGN PATENT DOCUMENTS</b>						
		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>COUNTRY</b>		
	BA					
	BB					
	BC					
	BD					
	BE					
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Ect.)</b>						
Ull	CA		Praag, H.M., "In Search of the Mode of Action of Antidepressants 5-HTP/Tyrosine Mixtures in Depressions" <i>Neuropharmacology</i> Vol. 22, No. 3B, pp. 433-770, 1983.			
	CB					
	CC					
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>			
[Signature]			12/12/05			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						



<b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				<b>ATTY DOCKET NO.:</b> H76.2N-8151- US06		<b>APPLICATION NO.:</b> 10/715912	
				<b>APPLICANT:</b> Martin C. Hinz			
				<b>FILING DATE:</b> November 18, 2003		<b>GROUP:</b> 1616	
<b>REFERENCE DESIGNATION</b>				<b>U.S. PATENT AND PUBLISHED APPLICATION DOCUMENTS</b>			
<b>EXAM'S INIT.</b>		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS/ SUBCLASS</b>	<b>FILING DATE IF APPROPRIATE</b>	
	AA						
	AB						
<b>FOREIGN PATENT DOCUMENTS</b>							
		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>COUNTRY</b>			
	BA						
	BB						
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
Ue	CA		Dr. Martin Hinz's and NeuroResearch Clinic, Inc.'s Joint Answer to Defendants' Amended Counterclaim.				
	CB		Answer of Defendants' to Hinz's Second Amended Complaint and Amended Counterclaim.				
	CC		Hinz's Second Amended Complaint.				
	CD		Deposition Transcripts of Dr. Martin C. Hinz (Vol. I of Nov. 17, 2004; and Vol. II of Feb. 24, 2005).				
	CE		Deposition Transcripts of Gottfried Kellermann, which is also on behalf of Neuroscience (Vol. I of Nov. 23, 2004; and Vol. II of Nov. 24, 2004).				
	CF		Deposition Transcript of Dr. William Wilson – Nov. 12, 2004.				
	CG		Deposition Transcript of Dave Peterson – Feb. 28, 2005.				
	CH		Affidavit of Dave Peterson with Attached Exhibits.				
	CI		Dr. Hinz's Responses to Defendants' First Set of Interrogatories (Nos. 23-27).				
Ue	CJ		Defendants' Amended Responses to Dr. Hinz's Third Set of Interrogatories (No. 26).				
<b>EXAMINER</b>			<b>DATE CONSIDERED</b> 3/20/06				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**(Use as many sheets as necessary)**

Sheet 1 of 1

**Complete if Known**

Application Number	10/715,912
Filing Date	January 14, 2004
First Named Inventor	Olaf Kruse, et al
Art Unit	1616
Examiner Name	M. Lamm
Attorney Docket Number	RIGHT-45043

[illegible][illegible]

### Data Considered

3/19/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinda Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 601.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Copied from 10715912 on 01/26/2006